Added to YB: 2024-07-02
Pitch date: 2024-07-01
AMPH [bearish]
Amphastar Pharmaceuticals, Inc.
+34.48%
current return
Author Info
No bio for this author
Company Info
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Market Cap
$1.3B
Pitch Price
$38.57
Price Target
N/A
Dividend
N/A
EV/EBITDA
6.42
P/E
8.70
EV/Sales
2.32
Sector
Pharmaceuticals
Category
N/A
Amphastar Pharmaceuticals: Market Challenges and Potential for Significant Decline
AMPH: 50% downside. Glucagon sales at risk as Fresenius returns, Viatris/Lupin enter. Epinephrine faces Pfizer return & new competition. Primatene MIST patent expires 2026, opening private label competition. Other products temporarily benefit from Pfizer tornado. 2025 EBITDA est. 40% below consensus. Risks ignored by sellside.
Read full article (2 min)